VEGF-B Molekülinformation
Molecule Name
Vascular endothelial growth factor B
Molekülalias
VRF,VEGFL,VEGFB,VEGF-B
Drug Development Progress
Anzahl der klinischen Arzneimittel4
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
VEGF-related factor，VRF，VEGFB，VEGF-B，VEGFL，Vascular Endothelial Growth Factor B
Molekülhintergrund
Vascular endothelial growth factor B (VEGFB) is also known as VEGF-related factor (VRF), is a secreted O-glycosylated protein, which belongs to the PDGF/VEGF growth factor family. VEGFB is expressed in all tissues except liver. Highest levels found in heart, skeletal muscle and pancreas. VEGFB is growth factor for endothelial cells. VEGF-B seems to play a role only in the maintenance of newly formed blood vessels during pathological conditions. VEGF-B also plays an important role on several types of neurons. It is important for the protection of neurons in the retina and the cerebral cortex during stroke and of motoneurons during motor neuron diseases such as amyotrophic lateral sclerosis.VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis.
VEGF-B Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| 4D-150 | 4D-150 | Phase 3 Clinical | 4d Molecular Therapeutics Inc | Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Wet Macular Degeneration | Details |
| Reflocibart | 2H-10; CSL-346 | Phase 2 Clinical | Csl Ltd | Diabetic Nephropathies | Details |
| PB-101 | PB-101 | Phase 1 Clinical | Panolos Bioscience Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| EB-105 | EB-105 | Phase 1 Clinical | Eluminex Biosciences (Suzhou) Ltd | Diabetic macular oedema; Diabetic Retinopathy | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Ziv-aflibercept | AVE-0005; BAY-865321 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Zaltrap | United States | Colorectal Neoplasms | Sanofi-Aventis U.S. Llc | 2012-08-03 | Adenocarcinoma, Follicular; Ascites; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Gliosarcoma; Leiomyosarcoma; Leukemia; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelomonocytic, Chronic; Lung Diseases; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Multiple Endocrine Neoplasia Type 1; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Neoplasm Metastasis; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Retinal Vein Occlusion; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Thyroid | Details |